12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NiCord: Completed Phase I/II enrollment

Gamida Cell completed enrollment of 11 patients in an open-label, U.S. Phase I/II trial evaluating co-transplantation of NiCord in combination with an unexpanded cord blood unit following myeloablative conditioning. The company previously reported data...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >